Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schelling, M.
Right arrow Articles by Schwaiger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schelling, M.
Right arrow Articles by Schwaiger, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 18, Issue 8 (April), 2000: 1689-1695
© 2000 American Society for Clinical Oncology

Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer

By M. Schelling, N. Avril, J. Nährig, W. Kuhn, W. Römer, D. Sattler, M. Werner, J. Dose, F. Jänicke, H. Graeff, M. Schwaiger

From the Departments of GynecologyNuclear Medicine, and Pathology, Technische Universität München, Munich, and Department of Gynecology, University Hospital Eppendorf, Hamburg, Germany.

Address reprint requests to Marcus Schelling, MD, Department of Gynecology, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr 22, 81675 München, Germany.

PURPOSE: To address the role of positron emission tomography (PET) using [18F]fluorodeoxyglucose (FDG) to monitor primary (neoadjuvant) chemotherapy in patients with locally advanced breast cancer.

PATIENTS AND METHODS: Quantification of regional FDG uptake of the breast acquired after the first and second courses of chemotherapy was compared with the baseline scan in 22 patients with a total of 24 breast carcinomas. To evaluate the predictive value of PET imaging, histopathologic response after completion of chemotherapy classified as gross residual disease (GRD) or minimal residual disease (MRD) served as the gold standard.

RESULTS: Significant differences in tracer uptake between nonresponding tumors (GRD) and responding lesions (MRD) were observed (P < .05) as early as after the first course of chemotherapy. Tracer uptake showed little change in tumors with GRD found later in pathologic analysis but decreased sharply to the background level in most tumors with MRD. After the first course, all responders were correctly identified (sensitivity 100%, specificity 85%) by a standardized uptake value decrease below 55% of the baseline scan. At this threshold, histopathologic response could be predicted with an accuracy of 88% and 91% after the first and second courses of therapy, respectively.

CONCLUSION: This study demonstrates that in patients with advanced breast cancer undergoing primary chemotherapy, FDG-PET differentiates responders from nonresponders early in the course of therapy. This may help improve patient management by avoiding ineffective chemotherapy and supporting the decision to continue dose-intensive preoperative chemotherapy in responding patients.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JNMHome page
K. McLarty, A. Fasih, D. A. Scollard, S. J. Done, D. C. Vines, D. E. Green, D. L. Costantini, and R. M. Reilly
18F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice
J. Nucl. Med., November 1, 2009; 50(11): 1848 - 1856.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Furth, I. G. Steffen, H. Amthauer, J. Ruf, D. Misch, S. Schonberger, C. Kobe, T. Denecke, B. Stover, H. Hautzel, et al.
Early and Late Therapy Response Assessment With [18F]Fluorodeoxyglucose Positron Emission Tomography in Pediatric Hodgkin's Lymphoma: Analysis of a Prospective Multicenter Trial
J. Clin. Oncol., September 10, 2009; 27(26): 4385 - 4391.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Bystrom, A. Berglund, U. Garske, H. Jacobsson, A. Sundin, P. Nygren, J.-E. Frodin, and B. Glimelius
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
Ann. Onc., June 1, 2009; 20(6): 1057 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. H. Lee, E. L. Rosen, and D. A. Mankoff
The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 2--Response to Therapy, Other Indications, and Future Directions
J. Nucl. Med., May 1, 2009; 50(5): 738 - 748.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
N. Avril, S. Sassen, and R. Roylance
Response to Therapy in Breast Cancer
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 55S - 63S.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. R. Benz, J. Czernin, M. S. Allen-Auerbach, W. D. Tap, S. M. Dry, D. Elashoff, K. Chow, V. Evilevitch, J. J. Eckardt, M. E. Phelps, et al.
FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas
Clin. Cancer Res., April 15, 2009; 15(8): 2856 - 2863.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Allen-Auerbach and W. A. Weber
Measuring Response with FDG-PET: Methodological Aspects
Oncologist, April 1, 2009; 14(4): 369 - 377.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al.
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose
J. Clin. Oncol., February 1, 2009; 27(4): 535 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. Medarova, L. Rashkovetsky, P. Pantazopoulos, and A. Moore
Multiparametric Monitoring of Tumor Response to Chemotherapy by Noninvasive Imaging
Cancer Res., February 1, 2009; 69(3): 1182 - 1189.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. R. Benz, M. S. Allen-Auerbach, F. C. Eilber, H. J.J. Chen, S. Dry, M. E. Phelps, J. Czernin, and W. A. Weber
Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas
J. Nucl. Med., October 1, 2008; 49(10): 1579 - 1584.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. K. Dunnwald, J. R. Gralow, G. K. Ellis, R. B. Livingston, H. M. Linden, J. M. Specht, R. K. Doot, T. J. Lawton, W. E. Barlow, B. F. Kurland, et al.
Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer
J. Clin. Oncol., September 20, 2008; 26(27): 4449 - 4457.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. R. Benz, V. Evilevitch, M. S. Allen-Auerbach, F. C. Eilber, M. E. Phelps, J. Czernin, and W. A. Weber
Treatment Monitoring by 18F-FDG PET/CT in Patients with Sarcomas: Interobserver Variability of Quantitative Parameters in Treatment-Induced Changes in Histopathologically Responding and Nonresponding Tumors
J. Nucl. Med., July 1, 2008; 49(7): 1038 - 1046.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
U. Tateishi, C. Gamez, S. Dawood, H. W. D. Yeung, M. Cristofanilli, and H. A. Macapinlac
Bone Metastases in Patients with Metastatic Breast Cancer: Morphologic and Metabolic Monitoring of Response to Systemic Therapy with Integrated PET/CT
Radiology, April 1, 2008; 247(1): 189 - 196.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. C. Hodgson and K. Y. Gulenchyn
Is There a Role for Positron Emission Tomography in Breast Cancer Staging?
J. Clin. Oncol., February 10, 2008; 26(5): 712 - 720.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al.
Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA, November 21, 2007; 298(19): 2289 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
H. S. Lim, W. Yoon, T. W. Chung, J. K. Kim, J. G. Park, H. K. Kang, H. S. Bom, and J. H. Yoon
FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations
RadioGraphics, October 1, 2007; 27(suppl_1): S197 - S213.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
E. L. Rosen, W. B. Eubank, and D. A. Mankoff
FDG PET, PET/CT, and Breast Cancer Imaging
RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
C. K. Kuhl
Current Status of Breast MR Imaging * Part 2. Clinical Applications
Radiology, September 1, 2007; 244(3): 672 - 691.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn
Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond
Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al.
Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography
J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Couturier, G. Jerusalem, J.-M. N'Guyen, and R. Hustinx
Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer.
Clin. Cancer Res., November 1, 2006; 12(21): 6437 - 6443.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. Linden, K. A. Krohn, R. B. Livingston, and D. A. Mankoff
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Clin. Cancer Res., October 1, 2006; 12(19): 5608 - 5610.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Serganova, J. Humm, C. Ling, and R. Blasberg
Tumor hypoxia imaging.
Clin. Cancer Res., September 15, 2006; 12(18): 5260 - 5264.
[Full Text] [PDF]

Home page
 JNMHome page
G. L. Cascini, A. Avallone, P. Delrio, C. Guida, F. Tatangelo, P. Marone, L. Aloj, F. De Martinis, P. Comella, V. Parisi, et al.
18F-FDG PET Is an Early Predictor of Pathologic Tumor Response to Preoperative Radiochemotherapy in Locally Advanced Rectal Cancer
J. Nucl. Med., August 1, 2006; 47(8): 1241 - 1248.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K.-H. Lee, S.-H. Lee, D.-W. Kim, W. J. Kang, J.-K. Chung, S.-A. Im, T.-Y. Kim, Y. W. Kim, Y.-J. Bang, and D. S. Heo
High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy.
Clin. Cancer Res., July 15, 2006; 12(14): 4232 - 4236.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cachin, H. M. Prince, A. Hogg, R. E. Ware, and R. J. Hicks
Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy
J. Clin. Oncol., July 1, 2006; 24(19): 3026 - 3031.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist, June 1, 2006; 11(6): 574 - 589.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. E. Juweid and B. D. Cheson
Positron-Emission Tomography and Assessment of Cancer Therapy
N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507.
[Full Text] [PDF]

Home page
 JCOHome page
D. S. Hawkins, S. M. Schuetze, J. E. Butrynski, J. G. Rajendran, C. B. Vernon, E. U. Conrad III, and J. F. Eary
[18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Outcome for Ewing Sarcoma Family of Tumors
J. Clin. Oncol., December 1, 2005; 23(34): 8828 - 8834.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
J. Clin. Oncol., October 20, 2005; 23(30): 7445 - 7453.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril
Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET
J. Nucl. Med., July 1, 2005; 46(7): 1144 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med., June 1, 2005; 46(6): 983 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Zhao, Y. Kuge, T. Mochizuki, T. Takahashi, K. Nakada, M. Sato, T. Takei, and N. Tamaki
Biologic Correlates of Intratumoral Heterogeneity in 18F-FDG Distribution with Regional Expression of Glucose Transporters and Hexokinase-II in Experimental Tumor
J. Nucl. Med., April 1, 2005; 46(4): 675 - 682.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Quon and S. S. Gambhir
FDG-PET and Beyond: Molecular Breast Cancer Imaging
J. Clin. Oncol., March 10, 2005; 23(8): 1664 - 1673.
[Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, J. F. Vansteenkiste, D. E. Morris, C. A. Dooms, A. H. Khandani, and M. A. Socinski
Seeking a Home for a PET, Part 3: Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer
Chest, November 1, 2004; 126(5): 1656 - 1666.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi, and D. A. Mankoff
18F-FDG Kinetics in Locally Advanced Breast Cancer: Correlation with Tumor Blood Flow and Changes in Response to Neoadjuvant Chemotherapy
J. Nucl. Med., November 1, 2004; 45(11): 1829 - 1837.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
S. Sironi, C. Messa, G. Mangili, B. Zangheri, G. Aletti, E. Garavaglia, R. Vigano, M. Picchio, G. Taccagni, A. D. Maschio, et al.
Integrated FDG PET/CT in Patients with Persistent Ovarian Cancer: Correlation with Histologic Findings
Radiology, November 1, 2004; 233(2): 433 - 440.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S.-J. Kim, S.-k. Kim, E. S. Lee, J. Ro, and S. h. Kang
Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy
Ann. Onc., September 1, 2004; 15(9): 1352 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J.M. van der Hoeven, N. C. Krak, O. S. Hoekstra, E. F.I. Comans, R. P.A. Boom, D. van Geldere, S. Meijer, E. van der Wall, J. Buter, H. M. Pinedo, et al.
18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography in Staging of Locally Advanced Breast Cancer
J. Clin. Oncol., April 1, 2004; 22(7): 1253 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Ott, U. Fink, K. Becker, A. Stahl, H.-J. Dittler, R. Busch, H. Stein, F. Lordick, T. Link, M. Schwaiger, et al.
Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial
J. Clin. Oncol., December 15, 2003; 21(24): 4604 - 4610.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
D. A. Mankoff, L. K. Dunnwald, J. R. Gralow, G. K. Ellis, E. K. Schubert, J. Tseng, T. J. Lawton, H. M. Linden, and R. B. Livingston
Changes in Blood Flow and Metabolism in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy
J. Nucl. Med., November 1, 2003; 44(11): 1806 - 1814.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. J. Biersack and H. Palmedo
Locally Advanced Breast Cancer: Is PET Useful for Monitoring Primary Chemotherapy?
J. Nucl. Med., November 1, 2003; 44(11): 1815 - 1817.
[Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger
Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
J. Clin. Oncol., July 15, 2003; 21(14): 2651 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Beaulieu, P. Kinahan, J. Tseng, L. K. Dunnwald, E. K. Schubert, P. Pham, B. Lewellen, and D. A. Mankoff
SUV Varies with Time After Injection in 18F-FDG PET of Breast Cancer: Characterization and Method to Adjust for Time Differences
J. Nucl. Med., July 1, 2003; 44(7): 1044 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Chesnay, E. Babin, J. M. Constans, D. Agostini, A. Bequignon, A. Regeasse, F. Sobrio, and S. Moreau
Early Response to Chemotherapy in Hypopharyngeal Cancer: Assessment with 11C-Methionine PET, Correlation with Morphologic Response, and Clinical Outcome
J. Nucl. Med., April 1, 2003; 44(4): 526 - 532.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics, March 1, 2003; 23(2): 315 - 340.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Kostakoglu and S. J. Goldsmith
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
J. Nucl. Med., February 1, 2003; 44(2): 224 - 239.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Downey, T. Akhurst, D. Ilson, R. Ginsberg, M. S. Bains, M. Gonen, H. Koong, M. Gollub, B. D. Minsky, M. Zakowski, et al.
Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial
J. Clin. Oncol., February 1, 2003; 21(3): 428 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Dowsett
Preoperative Models to Evaluate Endocrine Strategies for Breast Cancer
Clin. Cancer Res., January 1, 2003; 9(1): 502s - 510s.
[Abstract] [Full Text]

Home page
 JNMHome page
D. Vranjesevic, J. E. Filmont, J. Meta, D. H. Silverman, M. E. Phelps, J. Rao, P. E. Valk, and J. Czernin
Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients
J. Nucl. Med., March 1, 2002; 43(3): 325 - 329.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Bos, J. J.M. van der Hoeven, E. van der Wall, P. van der Groep, P. J. van Diest, E. F.I. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, et al.
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
J. Clin. Oncol., January 15, 2002; 20(2): 379 - 387.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
B. A. Goins and W. T. Phillips
The Use of Scintigraphic Imaging During Liposome Drug Development
Journal of Pharmacy Practice, October 1, 2001; 14(5): 397 - 406.
[Abstract] [PDF]

Home page
 JCOHome page
W. B. Eubank, D. A. Mankoff, J. Takasugi, H. Vesselle, J. F. Eary, T. J. Shanley, J. R. Gralow, A. Charlop, G. K. Ellis, K. L. Lindsley, et al.
18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer
J. Clin. Oncol., August 1, 2001; 19(15): 3516 - 3523.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber, K. Ott, K. Becker, H.-J. Dittler, H. Helmberger, N. E. Avril, G. Meisetschlager, R. Busch, J.-R. Siewert, M. Schwaiger, et al.
Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
J. Clin. Oncol., June 15, 2001; 19(12): 3058 - 3065.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. E. Mortimer, F. Dehdashti, B. A. Siegel, K. Trinkaus, J. A. Katzenellenbogen, and M. J. Welch
Metabolic Flare: Indicator of Hormone Responsiveness in Advanced Breast Cancer
J. Clin. Oncol., June 1, 2001; 19(11): 2797 - 2803.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps
A Tabulated Summary of the FDG PET Literature
J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93.
[Full Text] [PDF]

Home page
 JCOHome page
N. Avril, C. A. Rose, M. Schelling, J. Dose, W. Kuhn, S. Bense, W. Weber, S. Ziegler, H. Graeff, and M. Schwaiger
Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations
J. Clin. Oncol., October 20, 2000; 18(20): 3495 - 3502.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online